New injection targets stubborn love handles

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Having mild to moderate flank fat assessed by the investigator and sonography and/or caliper (≥2cm thickness of the fat tissue in posterior axillary lines at the level of ASIS) * Signing informed consent by the subject * Ability to follow study instructions and likely to complete all required visits * Agreement to abstain from any treatment to the flank region, including botulinum toxins, hyaluronic acid fillers, cosmetic surgery, laser/light therapy, chemical peels, etc., during the study Exclusion Criteria: * Planning to change lifestyle within the projected duration of the trial * History of liposuction surgery or laser lipolysis in the past 12 months or planning to have these procedures * Significant weight reduction in the past 6 months or planning for weight reduction within the projected duration of the trial * BMI \> 30 kg/m2 * Waist circumference \> 105 cm * Uncontrolled systemic diseases * Severe cardiovascular diseases * Known allergy or sensitivity to the study medication or its components * Females who are pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial * Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study and for the duration of the study. * Previous treatment to the flanks with hyaluronic acid fillers or semi-permanent filler in the past 12 months * Use of any permanent filler materials or silicone in the flanks * Subjects planning a cosmetic procedure in the treatment area during the study or with prior cosmetic procedures (i.e., surgery) in the treatment area or visible scars that may affect the evaluation * Subjects with volume deficit due to trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome), inherited disease, or HIV-related disease * Infection or dermatoses at the injection site * Evidence of recent alcohol or drug abuse * Medical and/or psychiatric problems that are severe enough to interfere with the study results * Known bleeding disorder or receiving medication that will likely increase the risk of bleeding after injection * Having hair that would interfere with evaluation and treatment of the flank area * Being prone to develop hypertrophic scarring * Having a history of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), hyaluronic acid products, or Streptococcal protein * Having porphyria * Having an active inflammation, infection, cancerous or precancerous lesion, or unhealed wound in the flank area * Having a condition or being in a situation that, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study